Potential of Farnesyl Transferase Inhibitors in Combination Regimens in Squamous Cell Carcinomas

SIMPLE SUMMARY: Current therapies for recurrent and metastatic squamous cell carcinomas (SCCs) are associated with poor patient outcomes, and options for later lines of treatment are very limited. In cases where single-agent therapy may be insufficient to eradicate the tumor, thus allowing outgrowth...

Descripción completa

Detalles Bibliográficos
Autores principales: Kessler, Linda, Malik, Shivani, Leoni, Mollie, Burrows, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582567/
https://www.ncbi.nlm.nih.gov/pubmed/34771475
http://dx.doi.org/10.3390/cancers13215310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582567/
https://www.ncbi.nlm.nih.gov/pubmed/34771475
http://dx.doi.org/10.3390/cancers13215310

Ejemplares similares